Summarized by Masters of Longevity from PR Newswire.
A news article about a biotech grant fueling cross‑border development of a novel gene therapy for ALS, outlining plans, partnerships, and next steps.
Key Takeaways
- AMED awarded about ¥6 billion over five years to support development of SOL-257.
- SOLA plans to advance SOL-257 toward human proof of concept in both the United States and Japan.
- SOLA's SOL-257 uses the JUMP70 platform to selectively target misfolded TDP-43 and engage HSP70.
